Neural Regeneration Research ›› 2022, Vol. 17 ›› Issue (12): 2675-2676.doi: 10.4103/1673-5374.335813

Previous Articles     Next Articles

Prothrombin kringle-2, a mediator of microglial activation: new insight in Alzheimer’s disease pathogenesis

Jae Man Lee, Sang Ryong Kim*   

  1. Department of Biochemistry and Cell Biology, Cell and Matrix Research Institute, School of Medicine, Kyungpook National University, Daegu, Korea (Lee JM)
    Brain Science and Engineering Institute, Kyungpook National University, Daegu, Korea (Kim SR)
    School of Life Sciences, BK21 FOUR KNU Creative BioResearch Group, Institute of Life Science and Biotechnology, Kyungpook National University, Daegu, Korea (Kim SR)
  • Online:2022-12-15 Published:2022-05-05
  • Contact: Sang Ryong Kim, PhD, srk75@knu.ac.kr.
  • Supported by:
    This work was supported by the National Research Foundation of Korea (NRF-2020R1A2C2007954) and the Korea Healthcare Technology R&D (HI21C1795) grants funded by the Korean government. 

PDF

71

Abstract: In 1907, Dr. Alois Alzheimer, a Bavarian-born German psychiatrist and neuropathologist, published an article describing the clinical and neuropathological features of an unclassified psychiatric disorder. The disorder was later named AD and is currently the most common brain disorder (Takata et al., 2021). AD involves the accumulation of amyloid-β (Aβ) and hyperphosphorylated tau proteins in the brain, which are associated with senile plaques and neurofibrillary tangles, respectively (Vergara et al., 2019; Takata et al., 2021). AD is characterized by cognitive impairment and memory loss with hippocampal neurodegeneration (Kim et al., 2021).